STAREE
2026
STAtin Therapy for Reducing Events in the Elderly
In 9,971 healthy adults aged 70 years or over, atorvastatin 40 mg improved one of two co-primary outcomes disability-free survival and major cardiovascular events compared with placebo.
Résultat
Efficacité: Co-primary: (1) disability-free survival, defined as survival free of dementia and persistent physical disability; (2) major cardiovascular events (cardiovascular death, non-fatal myocardial infarction or stroke; registry definition also lists coronary revascularisation)HR 0,70 (IC à 95 % 0,61-0,82) · P < 0,001
En dessous de 1 en faveur de atorvastatin 40 mg, au-dessus de 1 en faveur de placebo.
- Différence absolue
- 2,3 points
- NNT
- 44
La différence absolue et le NNT sont dérivés des taux d’événements.
Également rapporté: The other co-primary, disability-free survival, was unchanged: 12.8% vs 13.6% (HR 0.94, 95% CI 0.84-1.05; P = 0.25). Muscle, liver and diabetes-related adverse events were more common with atorvastatin; serious adverse events 2.7% in both arms.
- Sous-thème
- Primary prevention
- Schéma
- Double-blind, placebo-controlled RCT, 1:1, recruited through Australian general practice, average follow-up about 6 years planned, time-to-first-event analyses for each co-primary endpoint
- Pertinence
- Structure la pratique : un essai incontournable de la discipline.
- Source
- Zoungas S, et al. N Engl J Med. 2026; published online 28 August.doi 10.1056/nejmoa2607314
Discussion et critique
The trial general practice has been waiting for: a statin started after 70, in people without cardiovascular disease, diabetes or dementia. Cardiovascular events fall by 30% relative and 2.3 percentage points absolute over six years, roughly 43 people treated for one event avoided. The endpoint older patients are usually promised, years free of dementia and disability, did not move, and the entrants were healthy volunteers rather than the frail, comorbid 80-year-olds in whom the question is hardest.